96 related articles for article (PubMed ID: 20629739)
1. Cutaneous T-cell lymphoma cells are sensitive to rapamycin.
Kremer M; Sliva K; Klemke CD; Schnierle BS
Exp Dermatol; 2010 Sep; 19(9):800-5. PubMed ID: 20629739
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
Sors A; Jean-Louis F; Bégué E; Parmentier L; Dubertret L; Dreano M; Courtois G; Bachelez H; Michel L
Clin Cancer Res; 2008 Feb; 14(3):901-11. PubMed ID: 18245554
[TBL] [Abstract][Full Text] [Related]
3. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
4. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
5. [Inhibition of cell growth by rapamycin through targeting mammalian target of rapamycin signaling pathway in nasopharyngeal carcinoma].
Li YL; Zhang X; Liu Y; Li SS; Xie L; Zhang N; Liu XB; Tian YQ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Sep; 45(9):765-8. PubMed ID: 21092676
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
7. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies.
Foss FM
Semin Oncol; 2000 Apr; 27(2 Suppl 5):58-63. PubMed ID: 10877054
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines.
Bundscherer A; Hafner C; Maisch T; Becker B; Landthaler M; Vogt T
Oncol Rep; 2008 Feb; 19(2):547-53. PubMed ID: 18202806
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
11. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
12. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis.
Weppler SA; Krause M; Zyromska A; Lambin P; Baumann M; Wouters BG
Radiother Oncol; 2007 Jan; 82(1):96-104. PubMed ID: 17161482
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba JM; DeGraffenried L; Friedrichs W; Fulcher L; Grünwald V; Weiss G; Hidalgo M
Clin Cancer Res; 2003 Aug; 9(8):2887-92. PubMed ID: 12912932
[TBL] [Abstract][Full Text] [Related]
15. Cell signaling. New mTOR targets Grb attention.
Yea SS; Fruman DA
Science; 2011 Jun; 332(6035):1270-1. PubMed ID: 21659593
[No Abstract] [Full Text] [Related]
16. [Cutaneous lymphoma of the Sézary and Bouvrain type. Progress in physiopathologic and therapeutic outlook].
Bagot M
Bull Acad Natl Med; 1998; 182(5):927-37; discussion 937-8. PubMed ID: 9735499
[TBL] [Abstract][Full Text] [Related]
17. An expanding role for mTOR in cancer.
Guertin DA; Sabatini DM
Trends Mol Med; 2005 Aug; 11(8):353-61. PubMed ID: 16002336
[TBL] [Abstract][Full Text] [Related]
18. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
Fantin VR; Loboda A; Paweletz CP; Hendrickson RC; Pierce JW; Roth JA; Li L; Gooden F; Korenchuk S; Hou XS; Harrington EA; Randolph S; Reilly JF; Ware CM; Kadin ME; Frankel SR; Richon VM
Cancer Res; 2008 May; 68(10):3785-94. PubMed ID: 18483262
[TBL] [Abstract][Full Text] [Related]
19. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity.
Nogueira LM; Dunlap SM; Ford NA; Hursting SD
Endocr Relat Cancer; 2012 Feb; 19(1):57-68. PubMed ID: 22143497
[TBL] [Abstract][Full Text] [Related]
20. In vivo imaging of cutaneous T-cell lymphoma migration to the skin.
Hoeller C; Richardson SK; Ng LG; Valero T; Wysocka M; Rook AH; Weninger W
Cancer Res; 2009 Apr; 69(7):2704-8. PubMed ID: 19318575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
